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Abstract
Background: Psychotropic drug use and alcohol consumption among older adults need to be monitored over
time as their use or combined use bears risks of harms. Representative data on changes in prevalence, patterns and
co-relates of substance use are lacking in Germany.
Methods: Participants were older adults (60–79 years) from two German National Health Surveys: 1997–99 (GNHIES98,
N = 1,606) and 2008-11 (DEGS1, N = 2,501). Included were drugs acting on the nervous system used during the last
7 days. Alcohol consumption was measured by frequency (daily drinking) and quantity (risky drinking: ≥20/10 g/day
alcohol for men/women). Changes in prevalence adjusted for potential socio-economic and health-related
confounders were calculated by logistic regression models approximated by the SAS LSMEANS statement.
Results: The prevalence of overall psychotropic drug use (20.5% vs. 21.4%) remained constant between the two
surveys. Significant changes were observed in the use of some psychotropics (all GNHIES98 vs. DEGS1): Synthetic
antidepressants (3.9% vs. 6.9%), St. John’s wort (2.9% vs. 1.1%), benzodiazepines (3.7% vs. 2.5%), benzodiazepine
related drugs (0.2% vs. 0.8%), narcotic analgesics (3.0% vs. 4.1%), anti-dementia drugs (2.2% vs. 4.2%) and anti-
epileptics (1.0% vs. 2.3%). Significant changes were also observed in long-term use of synthetic anti-depressants
(3.2% vs. 5.9%), St. John’s wort (2.0% vs. 0.6%) and opioid analgesics (1.0% vs. 2.2%). Further, we found significant
changes in benzodiazepines use (3.3% vs. 1.4%) among men, opioids use (2.9% vs. 7.3%) among people with a
lower social status, and overall psychotropics (26.8% vs. 32.5%) as well as opioids use (4.4% vs. 8.1%) among those
with a worse health status. Moderate alcohol consumption increased significantly (58.0% vs. 66.9%). Risky drinking
remained unchanged (16.6% vs. 17.0%). In spite of significant increases in daily alcohol drinking (13.2% vs. 18.4%)
psychotropic drug use combined with daily drinking remained unchanged (1.8% vs. 2.7%).
Conclusions: Although prevalence of overall psychotropic drug use remained stable, changes in the use of some
psychotropic drug groups and alcohol consumption patterns have been observed. Further studies are required to
investigate resulting health consequences and public health relevance of those outcomes.
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Background
The prevalence of psychotropic drug and alcohol-
interactive medicine use rises sharply with older age [1].
An age-related increase of multi-morbidity and poly-
pharmacy bears higher risks of adverse drug reactions
and a reduced drug metabolism in older people aggra-
vates those risks [2]. Potential adverse health outcomes
of psychotropic drug use such as falls, strokes or mortal-
ity are described in literature [3–5].
The long-term use of some psychotropic drugs, such
as opioids and benzodiazepines, can lead to dependency
and addiction. With the exception of some medically ne-
cessary indications those drugs should be used only for a
short period [6, 7].
Psychotropic drugs of phytoceutical origin are also of
interest as in Germany the use of alternative medicine
has a long tradition and is very common [8].
Alcohol has a psychotropic effect, an addictive potential,
and bears health risks for the elderly. According to the
Organisation for Economic Co-operation and Develop-
ment (OECD) alcohol consumption in Germany is with
11 l per capita higher than the average European con-
sumption level of 10 l. Additionally, among adults about
every sixth woman and about every third man consumes
alcohol above tolerable upper levels for healthy adults of
10-12 g/20-24/day for women/men [9, 10]. The combined
use of alcohol and psychotropic medicine may aggravate
potential risks of both substances [5].
Drug use changes over time as new drugs are intro-
duced into the market and indications for existing drugs
might be changed. Also, changes in drug use might be
influenced by changes in guidelines for the use of drugs.
Transparency on the use of medications and on changes
in the use over time is a prerequisite for an informed
Public Health Policy.
Prescription data from the statutory health insurance
system can provide information on changes in prescrip-
tion over time but cannot reproduce the real consump-
tion of medicines. Patients might not take all tablets of a
package; self-medication and private prescriptions are
not recorded by prescription data. Further, health insur-
ance data cannot be linked with a variety of population
characteristics, such as socio-economic and health be-
havior factors (e.g. alcohol consumption).
In Germany, population based data from two compar-
able surveys - the German National Health Interview
and Examination Survey 1997-99 (GNHIES98) and the
German Health Interview and Examination Survey for
Adults 2008-11 (DEGS1) – with data on the use of psy-
chotropic drugs and alcohol in the older population
(60–79 years) are available. A cross-sectional analysis of
psychotropic drug use, alcohol consumption and the
combined use of both substances based on DEGS1 data
has been conducted by the authors recently [11].
Representative population based information on changes
over time in psychotropic substance use among the elderly
and information on changes in the use of psychotropics
according to socio-economic and health-behavior factors
are lacking in Germany.
In the present work we analyzed changes in psycho-
tropic drug use, alcohol consumption, and the con-
comitant use of psychotropic drugs and alcohol
between 1997-99 and 2008-11. Additionally, we exam-
ined changes in long-term use of selected subgroups of
psychotropic drugs. Further, by analyzing changes over
time according to socio-economic and health-related
factors we identified particularly vulnerable groups
among older adults in Germany.
Methods
Study population
Analyses conducted in this study were based on data from
two nationally representative surveys among non-
institutionalized adults: GNHIES98 (1997-99) and DEGS1
(2008-11). Both surveys were conducted by the Robert
Koch Institute (RKI) and followed largely the same
sampling strategy and study protocol. This has been
described in detail previously [12, 13]. Briefly, both sur-
veys recruited participants via a two-stage sampling
design. In the first stage a nationwide selection of com-
munities which were representative of location, size,
and structure of German communities was conducted
(GNHIES98: 120 and DEGS1: 180 communities). In a
second stage a representative sample of the 18–79 year
old population was drawn from local population regis-
tries of the chosen communities. All participants from
GNHIES98 (N = 7.124) were invited to re-participate in
DEGS1. 3,959 women and men (response rate 62%)
followed this invitation. In order to achieve a nationally
representative sample 4,193 first time participants were
also included in DEGS1 (response rate 42%), amounting
to a total study population of N = 8.152. Non-responder
analyses in both surveys displayed no significant differ-
ences between participants and non-participants re-
garding demographic factors [14, 15].
The present analyses focused on men and women aged
60–79 years (GNHIES98: N = 1,615 and DEGS1: N =
2,508). Among those only participants who completed the
interview on medication use were included (GNHIES98:
N = 1,606 and DEGS1: N = 2,501).
Data collection
Both surveys employed identical data collection methods
including self-administered questionnaires, medical ex-
aminations, physical measurements, laboratory tests,
standardized physician administered computer assisted
personal interviews (CAPI), and standardized personal
interviews on medicine use [12]. Information on socio-
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demographic factors (e.g. age, sex, region of residence,
household size, income, profession, and education) as
well as health-related factors (e.g. self-perceived health
status, presence of an officially certified disability, and
alcohol consumption) was collected via standardized,
self-administered questionnaires [12].
Identification of psychotropic drug use and alcohol
consumption
In the invitation letter participants were asked to bring
along original packages of the drugs they had taken dur-
ing the preceding 7 days, including Over-The Counter
(OTC) products and dietary supplements. Detailed infor-
mation on each preparation was recorded by trained
health professionals. For all drugs the brand name, indi-
cation, frequency (taken when needed or regular), and
duration of use were recorded. The preparations were
classified by the Anatomical Therapeutic Chemical
(ATC) codes. In the present analyses we included drugs
belonging to the nervous system class (ATC code N00).
The following drug groups were included: Narcotic anal-
gesics (N02A) and aspirin if combined with caffeine
(N02BA71), all anti-epileptics (N03), all anti-parkinson
drugs (N04), all psycholeptics (N05) with hypnotics and
sedatives (N05C), benzodiazepines (N05BA, N05CD,
N03AE01)) and benzodiazepine-related drugs (N05CF),
all psychoanaleptics (N06) with anti-depressants (N06A)
and anti-dementia drugs (N06D), all other nervous sys-
tem drugs (N07) as well as opiates used as antitussives
(ATC code R05DA), and psychotropic drugs with herbal
active ingredients (ATC code N05CP or N06AP or
N06DP). Excluded were: Other analgesics and antipy-
retics such as aspirin and paracetamol (ATC code
N02B), local anesthetics (ATC code N01B), homeopathic
drugs of the ATC class N00, and drugs with indistinctive
active ingredients. Concerning frequency and duration
of drug use we differentiated between drug use “if
needed”, “regular, < 3 months” and “regular, ≥ 3 months”.
The cut-off point of ≥ 3 months for long-term use was
chosen as some psychotropic drugs can lead to addic-
tion. Guidelines on the use of opioids in non-cancer
pain recommend an application time of no longer than
3 months [6]. The recommendations for limitations in
the use of benzodiazepines are even shorter [7, 16].
Anti-depressants have to be taken for a longer period
in order to have a therapeutic effect, are usually not
taken “only if needed”, and their dependency potential
is much lower compared to opioids or benzodiazepines
[17]. Changes in the prevalence of psychotropic drug
use were analyzed for drugs of the above listed ATC
classes. Additionally, changes in long-term use were an-
alyzed for the most frequently used drug groups antide-
pressants, as well as for benzodiazepines and opioids as
their long-term use harbors a potential for dependency
and addiction.
Alcohol consumption during the preceding 12 months
was recorded via a standardized food-frequency ques-
tionnaire and was classified according to frequency as
well as quantity. Within the classification according to
frequency we differentiated between alcohol consump-
tion “at least once a week” (weekly) and “at least once a
day” (daily). For the classification according to quantity
the mean amount of pure alcohol consumed in grams
per day was calculated according to methods previously
described [18]. Alcohol consumption according to quan-
tity was classified as “moderate drinking” and “risky
drinking”. The definition of risky drinking varies
greatly internationally [19]. In Germany for healthy
younger people a limit of ≥10–12 g/day for women
and ≥20–24 g/day for men is assumed [18, 19]. As
older people could be at risk when consuming much
smaller amounts of alcohol, and as there are no inter-
nationally agreed limits for risky alcohol consumption
among the elderly, we adopted the lower limits of >0
to <10 g for women and >0 to <20 g for men to clas-
sify “moderate drinking” and ≥10 g/day for women
and ≥20 g/day for men to classify “risky drinking”. For
measurement of the combined use of psychotropic
drugs and alcohol we chose the categories “daily
drinking“and “daily risky drinking” as this offers the
strongest probability that both substances are taken
simultaneously.
Co-variables
As co-variables we included sex, age group (60–69 and
70–79 years), social status according to a total score of a
composite social status index [20] (lower, middle, upper),
living alone (only one person living in a household), and
urbanity (rural: <5000; small city: 5000 - <20.000; medium
sized city: 20.000 - <100.000; large city: 100.000 and more
residents). To determine region of residence we divided
Germany into three commonly described geographical
areas, each including several federal states: Northern
Germany (Berlin, Brandenburg, Bremen, Hamburg,
Lower Saxony, Mecklenburg-West Pomerania, and
Schleswig-Holstein); Central Germany (Hesse, North
Rhine-Westphalia, Saxony, Saxony-Anhalt, and Thur-
ingia) and Southern Germany (Baden-Württemberg,
Bavaria, Rhineland-Palatinate and Saarland). The
following health-related co-variables were included:
Self-assessed health status dichotomized as “better”
(very good or good) and “worse” (moderate, bad, and
very bad), having an officially certified disability (yes,
no) and exposure to polypharmacy (five or more dif-
ferent products, prescribed and/or OTC within the
past seven days, excluding psychotropic drugs).
Wolf et al. BMC Psychiatry  (2017) 17:90 Page 3 of 12
Statistical analyses
To generate population representative prevalence rates
of psychotropic substance use in trend analyses a
weighting factor was introduced. This served the cor-
rection of any deviations in the samples from popula-
tion structure regarding age, sex, region of residence,
municipality size, nationality, and educational level in
comparison to the German population of the 31th
December 2010 [15]. Re-participation probability of
GNHIES98 participants was also included for calcula-
tion of the weighting factor. Characteristics of the
population were analyzed via descriptive statistics. For
the prevalence of psychotropic drug use and alcohol
consumption, we calculated the absolute changes in
percentage points (%) and 95% Confidence Intervals
(95% CIs) between surveys, both unadjusted and ad-
justed for co-variables. The adjusted changes in per-
centage points were derived from the predictive
margins calculated from a logistic regression model [21,
22]. First-order interactions between the survey year
and the co-variates were tested and included in the
model if p < 0.10. The predictive margins were calcu-
lated as the adjusted probabilities predicted by the
model, averaged over all subjects in the model and as-
suming that the co-variable distribution in GNHIES98
and DEGS1 was identical. The standard errors and cor-
relation of the predictive margins were approximated
by the SAS LSMEANS statement and used in the calcu-
lation of the 95% CIs for the adjusted changes in
percentage points. SAS 9.4 survey procedures for com-
plex samples (SAS Institute Inc., Cary, NC) or SPSS
complex samples module were used for statistical ana-
lyses. A probability level for statistically significant




There were no significant differences between the
GNHIES98 and the DEGS1 population concerning
socio-demographics (age, sex, urbanity, regions of resi-
dence, and social status) as well as the proportion of
people living alone or having an officially certified dis-
ability (Table 1). Significant differences between the two
survey-populations were found for “self-assessed health
status” and “polypharmacy”. More people rated their
health as better in 2008–11 than in 1997–99. Contrarily,
more people in 2008–11 used polypharmacy (Table 1).
Changes in psychotropic drug use, alcohol consumption
and combined use of both substances
Table 2 depicts the changes in psychotropic drug use and
alcohol consumption from 1997–99 to 2008–11 adjusted
for sex, age group, region of residence, community size,
social status, polypharmacy, living alone and having a rec-
ognized disability. In the models self-assessed health status
was not included as an adjusting factor as it correlates to a
large extend with polypharmacy. Repeated analyses with
self-assessed health status replacing polypharmacy in
models showed no significant changes.
After adjustments no changes over time in the use of
overall synthetic or overall phytoceutical psychotropic
drugs were found. In all categories of alcohol consump-
tion we observed rising prevalence rates, but they were
only significant for daily (adjusted change: +9.6%, p-
< .0001) and moderate drinking (adjusted change:
+8.9% p- < .0001). Combined use of psychotropic drugs
and daily or daily risky alcohol consumption remained
unchanged (Table 2).
Changes in the use of specific psychotropic drug groups
Table 3 presents the changes in the use of specific
groups and subgroups of psychotropic drugs between
the surveys of 1997–99 and 2008–11. Prevalence of
overall anti-depressants use (6.4% vs. 7.9%) has not
changed but we found significant changes in the fol-
lowing subgroups: The use of the phytoceutical anti-
depressant St. John’s wort declined (adjusted change:
-5.0%, p = 0.001) and the use of synthetical antidepres-
sants increased (adjusted change: +6.0%, p = 0.001).
Among synthetical antidepressants we observed a sig-
nificant rise in the use of selective serotonin reuptake
inhibitors (SSRIs) (adjusted change: +4.1%, p = <0.001).
Prevalence in the use of hypnotics & sedatives (3.6% vs.
3.3%) or overall benzodiazepines & benzodiazepine-
related drugs (Z-drugs) (3.9% vs. 2.4%) remained
unchanged. However, looking at benzodiazepine and Z-
drug use separately, we found a significant decline in
the use of benzodiazepines (adjusted change: -3.4%, p
= 0.024) and a significant rise in the use of Z-drugs
(adjusted change: +1.3%, p = < 0.001). Further, we ob-
served significant rises in the use of overall anti-dementia
drugs (adjusted change: +3.2%, p = 0.001) - especially
Ginkgo biloba (adjusted change: +2.4%, p = 0.001) -, nar-
cotic analgesics (N02A) (adjusted change: +3.9%, p =
0.026), and anti-epileptics (adjusted change: +3.6%, p =
<0.001). There were no significant changes in the use of
anti-parkinson drugs (1.1% vs. 1.2%) and anxiolytics (2.4%
vs. 2.2%) within the observation period (Table 3).
Changes in long-term use of psychotropic drugs
Figure 1 depicts changes in prevalence of long-term use
for some selected psychotropic drugs between the sur-
veys of 1997–99 and 2008–11. Long-term use of opioid
analgesics (1.0% vs. 2.2%, p = 0.045) was more than twice
as high and long-term use of benzodiazepines (2.0% vs.
1.0%, p = 0.059) was halved in 2008–11. Long-term use
of synthetical anti-depressants (3.1% vs. 5.9%, p = 0.002)
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increased significantly while long-term use of phytoceu-
tical anti-depressants (St. John’s wort) decreased signifi-
cantly (2.0% vs. 0.5%, p = <0.001) (Fig. 1).
Changes in psychotropic substance use according to
socio-economic and health-related factors
Psychotropic drug use and risky alcohol consumption
among elderly participants of the surveys of 1997–99
and 2008–11 differentiated according to sex, social sta-
tus and self-assessed health status are presented in
Figs. 2a and b. Among people with a worse health status
overall psychotropic drug use increased from 26.8% to
32.5% (Fig. 2a) (p = 0.024) and the use of opioid analge-
sics rose from 4.4% to 8.1% (Fig. 2b) (p = 0.004). Further,
among people with a lower social status the use of
opioid analgesics increased from 2.9% to 7.3% (Fig. 2b)
Table 1 Descriptive characteristics of study populations aged 60-79 years. National Health Interview and Examination Surveys
GNHIES98 (1997–99) and DEGS1 (2008–11)
GNHIES98a (N = 1606) DEGS1a (N = 2501) P value
n % 95% C n % 95% CI
Sex
Men 727 47.0 44.7 49.3 1227 46.9 44.5 49.3 .962
Women 879 53.0 50.7 55.3 1274 53.1 50.7 55.5
Age groups
60–69 years 1031 52.5 49.9 55.1 1393 52.6 50.6 54.5 .970
70–79 years 575 47.5 44.9 50.1 1108 47.4 45.5 49.4
Living alone
Yes 355 24.2 21.0 27.7 506 21.3 19.2 23.6 .084
No 1174 75.8 72.3 79.0 1983 78.7 76.4 80.8
Urbanityb
Rural 382 19.9 13.2 29.0 428 16.3 11.0 23.6 .113
Small city 333 18.9 12.4 27.8 586 25.6 19.0 33.6
Medium sized city 406 28.1 20.0 37.9 733 27.8 21.2 35.6
Large city 485 33.1 24.1 43.4 754 30.2 23.3 38.2
Region of residencec
Northern Germany 375 26.0 18.0 35.9 641 25.6 19.1 33.5 .979
Central Germany 781 40.7 31.5 50.7 1137 41.4 33.6 49.6
Southern Germany 450 33.3 24.3 43.7 723 33.0 25.7 41.2
Social status
Lower 374 26.1 22.8 29.6 436 24.1 21.2 27.3 .393
Middle 935 59.1 55.8 62.4 1489 59.3 56.3 62.3
Upper 233 14.8 12.1 17.9 562 16.5 14.6 18.7
Officially certified disability
Yes 371 26.0 23.3 29.0 647 29.1 26.4 31.9 .079
No 1168 74.0 71.0 76.7 1797 70.9 68.1 73.6
Self-assed health status
Better 781 47.8 44.4 51.1 1498 58.1 55.5 60.7 <.0001
Worse 825 52.2 48.9 55.6 985 41.9 39.3 44.5
Polypharmacyd
Yes 466 30.0 27.1 33.0 993 38.8 36.5 41.2 <.0001
No 1140 70.0 67.0 72.9 1508 61.2 58.8 63.5
a Standardized to the population of 1.12.2010
b Urbanity: Rural (<5000 residents), small city (5000 - <20.000), medium sized city (20.000 - <100.000), large city (100.000 and more residents)
c Regions: Northern Germany (federal states: Berlin, Brandenburg, Bremen, Hamburg, Lower Saxony, Mecklenburg-Vorpommern, Schleswig-Holstein),
Central Germany (Hesse, North Rhine-Westphalia, Saxony, Saxony-Anhalt, Thuringia), Southern Germany (Baden-Württemberg, Bavaria,
Rhineland-Palatinate, Saarland)
d Polypharmacy: Use of five or more different prescribed and OTC drugs (excluding psychotropics) in the last seven days
Missing values: Living alone (GNHIES98 n = 77, DEGS1 n = 12), social status (64, 14), officially certified disability (67, 57), self-assed health status (0, 18)
Figures in bold denote statistical significance
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(p = 0.018) and among men the use of benzodiazepines
decreased from 3.3% to 1.4% (Fig. 2b) (p = 0.023).
Figure 2a and b show that for the use of antidepres-
sants, benzodiazepines and opioids gender gaps were
widening and narrowing for risky drinking. Gaps be-
tween lower and upper social status were widening con-
cerning the use of all groups of psychotropic drugs and
narrowing for risky drinking. Gaps were also widening
between those with a better and a worse health status
for the use of overall psychotropic drugs, antidepres-
sants, and opioids. Between those with a better and a
worse health status gaps were also widening concerning
risky drinking. This was due to fewer people with a
worse health status and more people with a better health
status engaging in risky drinking.
Discussion
Main findings
Overall psychotropic drug use remained stable while
daily and moderate alcohol drinking increased between
the two surveys of 1997-99 and 2008-11. Changes were
observed for specific psychotropic drug groups and sub-
groups. Significant increases were found in the use of
synthetical antidepressants (particularly SSRIs), Z-drugs,
overall anti-dementia drugs (especially Ginkgo biloba),
opioid analgesics, and anti-epileptics. The use of the
phytoceutical antidepressant St. John’s wort and of ben-
zodiazepines declined significantly. Significant rises were
observed in the long-term use of opioid analgesics and
synthetical anti-depressants, while the long-term use of
benzodiazepines and St. John’s wort decreased signifi-
cantly. Among people with a worse health status the use
of overall psychotropic drugs and opioid analgesics in-
creased significantly. Among those with a lower social
status the use of opioid analgesics increased significantly
while among men the use of benzodiazepines decreased
significantly.
Comparison to other studies
A comparison of prevalence rates has been described in
our previous study [11]. In the present work we com-
pared changes over time and direction of changes and
found predominantly similar tendencies in psychotropic
drug use in western countries. Prevalence rates of psy-
chotropic drug use might vary between studies due to
differences in observation periods, years of study con-
duction, settings, age groups, and drugs included. Differ-
ences in psychotropic drug use between countries could
be due to differences in health care- and reimbursement
systems, in understanding of psychiatric problems, cul-
tural attitudes or traditions (i.e. Germany has a long
tradition of phytoceutical therapies) [8, 23].
Changes in overall psychotropic drug use and alcohol
consumption
In our study overall psychotropic drug use remained
unchanged between the two surveys of 1997-99 and
2008-11. A Finnish study [24] also reported unchanged
Table 2 Changes in the prevalence of psychotropic drug use and alcohol consumption among adults aged 60–79 years in
Germany. National Health Interview and Examination Surveys GNHIES98 (1997–99) and DEGS1 (2008–11)
GNHIES98a DEGS1a Change in % (GNHIES98-DEGS1)
n % 95% CI n % 95% CI Unadjusteda 95% CI p value Adjusteda,b 95% CI p value
All psychotropic drugs
(synthetics & phytoceuticals)
313 20.5 18.2 22.9 518 21.4 19.3 23.7 1.0 -2.2 4.1 .554 -0.3 -5.4 4.8 0.897
All phytoceuticals 107 6.7 5.4 8.3 158 6.5 5.4 7.8 -0.2 -1.9 1.5 .827 -0.1 -2.3 2.2 0.956
All synthetics 223 14.6 12.6 16.9 404 16.9 14.9 19.1 2.3 -0.8 5.3 .145 1.5 -4.3 7.2 0.622
Weekly alcohol use
(at least once a week)
739 48.8 45.5 52.2 1295 51.0 48.1 53.9 2.1 -2.0 6.2 .305 4.0 -3.8 11.8 0.319
Daily alcohol use
(at least once a day)
185 13.2 11.1 15.5 468 18.4 16.3 20.7 5.2 2.4 8.1 .001 9.6 5.7 13.6 <.001
Moderate drinkingc 919 58.0 54.6 61.3 1659 66.9 64.1 69.5 8.9 4.9 13.0 <.001 8.9 4.6 13.1 <.001
Risky drinkingd 240 16.6 14.2 19.4 459 17.0 14.9 19.2 0.3 -2.7 3.3 .836 0.4 -2.0 2.9 0.724
Psychotropic drugs
+ daily drinking
25 1.8 1.2 2.7 76 2.7 2.0 3.7 0.9 -0.2 2.1 .122 1.3 -0.3 2.8 0.105
Psychotropic drugs
+ daily risky drinking
20 1.5 .9 2.4 59 2.1 1.5 2.9 0.6 -0.4 1.6 .274 0.7 -0.5 1.9 0.258
a Standardized to the population of 31.12.2010
b Adjusted for sex, age group, region, community size, social status, polypharmacy, living alone, recognized disability
c Moderate drinking: average daily consumption of alcohol between >0 and <10 g for women, and between >0 and < 20 g for men
d Risky drinking: average daily consumption of alcohol ≥10 g for women, and ≥20 g for men
Figures in bold denote statistical significance
Wolf et al. BMC Psychiatry  (2017) 17:90 Page 6 of 12
prevalences of overall psychotropic drug use between
1990-91 and 1998-99 and a Swedish study [25] observed
unchanged prevalences among cognitive intact elderly,
but significant rises among cognitive impaired elderly be-
tween 1987 and 2007. Contrarily, significant increases in
overall psychotropic drug use were reported by an US [26]
and a Spanish study [27]. However, the US-study included
only a three year observation period (1999–2002) which
might cover a period with a higher increase and the
Spanish study (1993 and 2003) involved older age
groups (65+). Further, comparisons between countries
might be difficult for the above described reasons.
In our study both, daily and moderate alcohol drinking
increased significantly. Other studies described rises in
risky drinking among the elderly [28, 29]. As in our ana-
lyses, higher prevalence rates of alcohol consumption
were found among men [28–30] and narrowing gender
gaps in the US, Australia, and European countries were
described by a literature review of Keyes et al. [30] and a
Swedish study [31]. Consistent with our findings, risky
drinking was associated with a higher social status in
some studies [32, 33]. In contrast to our results, risky
drinking was associated with lower social class in an
inner city study in the UK [34].
The growing alcohol consume among older people
could be due to more healthy life years and improved in-
comes of the elderly. The rising alcohol consume in
women could be due to a greater social acceptance and
more financial independence [35]. Further, cohort effects
and the impact of socio-historical contexts could influ-
ence drinking behavior [29].
Changes in prevalence of specific psychotropic drug
groups and subgroups
The significant increase in the use of synthetical antide-
pressants among the elderly, particularly of SSRIs, is also
Table 3 Changes in the prevalence of the use of specific psychotropic drug groups among adults aged 60-79 years in Germany.
National Health Interview and Examination Surveys GNHIES98 (1997–99) and DEGS1 (2008–11)
GNHIES98a DEGS1a Change in % (GNHIES98-DEGS1)
n % 95% CI n % 95% CI Unadjusteda 95% CI p value Adjusteda,b 95% CI p value
1. All anti-depressants (St. John’s wort
and all synthetical antidepressants)
96 6.4 5.2 7.9 173 7.9 6.5 9.5 1.4 -0.6 3.4 .157 1.7 -1.8 5.2 0.343
1.1 St. John’s wort (N06AP) 47 2.9 2.1 3.9 27 1.1 0.8 1.7 -1.7 -2.7 -0.8 <.001 -5.0 -7.9 -2.0 0.001
1.2 All synthetical antidepressants 54 3.9 2.9 5.2 151 6.9 5.5 8.5 3.0 1.2 4.8 .001 6.0 2.5 9.4 0.001
1.2.1. NSMRIsc (N06AA) 45 3.6 2.6 4.8 80 3.8 2.8 5.2 0.3 -1.3 1.8 .741 0.4 -2.7 3.5 0.806
1.2.2. SSRIsd (N06AB) 3 0.3 0.1 1.0 47 2.0 1.4 2.7 1.7 1.0 2.4 .001 4.1 2.4 5.8 <.0001
2. All hypnotics & sedatives (synth.,
antihistamines and phytoceuticals)
62 3.6 2.8 4.8 98 3.3 2.6 4.3 -0.3 -1.6 1.0 .644 -1.3 -3.5 0.9 0.234
2.1 All synth. (N05C) and
antihistamines (N05CM)
31 1.6 1.1 2.4 52 1.6 1.1 2.2 0.0 -0.9 0.8 .921 -0.1 -1.7 1.4 0.861
2.1.1. Hypnotics & sedatives (N05C) 31 1.6 1.1 2.4 42 1.3 0.9 1.9 -0.3 -1.1 0.5 .430 -0.6 -2.2 0.9 0.412
2.2. All phytoceuticals 32 2.1 1.4 3.0 51 1.9 1.3 2.6 -0.2 -1.2 0.8 .703 -0.6 -1.9 0.6 0.307
2.2.1. Valerian (N05CP) 28 1.8 1.2 2.7 42 1.5 1.0 2.1 -0.3 -1.2 0.6 .453 -0.5 -1.7 0.7 0.408
3. Benzodiazepines and
benzodiazepine-related drugs
64 3.9 2.9 5.2 84 3.3 2.4 4.4 -0.6 -2.1 0.8 .389 -2.0 -5.0 0.9 0.176
3.1. Benzodiazepines
(N05BA, N05CD, N03AE01)
57 3.7 2.8 5.0 57 2.5 1.8 3.5 -1.2 -2.6 0.2 .081 -3.4 -6.3 -0.4 0.024
3.2. Benzodiazepine-related
drugs (Z-drugs) (N05CF)
8 0.2 0.1 0.5 28 0.8 0.5 1.3 0.6 0.2 1.0 .003 1.3 0.6 2.1 <0.001
4. All anti-dementia drugs
incl. ginkgo biloba
34 2.2 1.4 3.4 97 4.2 3.3 5.4 2.0 0.7 3.3 .005 3.2 1.3 5.1 0.001
4.1. Ginkgo biloba (N06DP01) 34 2.2 1.4 3.4 88 3.8 2.9 4.8 1.6 0.3 2.8 .022 2.4 1.0 3.8 0.001
5. Narcotic analgesics (N02A) 39 3.0 2.1 4.2 96 4.1 3.2 5.3 1.2 -0.3 2.6 .121 3.9 0.5 7.3 0.026
6. Anti-epileptics (N03) 14 1.0 0.5 1.7 63 2.3 1.7 3.3 1.4 0.4 2.3 .008 3.6 1.7 5.5 <0.001
7. Antiparkinson drugs (N04) 19 1.1 .7 1.8 32 1.2 0.7 2.0 0.1 -0.7 0.9 .806 -0.1 -1.4 1.3 0.934
8. Anxiolytics (N05B) 34 2.4 1.6 3.5 48 2.2 1.5 3.1 -0.2 -1.4 1.0 .751 -1.2 -3.2 0.9 0.268
astandardized to the population of 31.12.2010
b adjusted for sex, age group, region, community size, social status, polypharmacy, living alone, recognized disability
cNon-Selective Monoamine Reuptake Inhibitors
dSelective Serotonin Reuptake Inhibitors
Figures in bold denote statistical significance
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confirmed by other population based studies [24–26,
36, 37] as well as by studies based on dispensing-data
[38, 39]. In our analysis the use of phytoceutical antide-
pressants (St. John’s wort) decreased significantly but
international literature on changes/trends in the use of
St. John’s wort is scarce. An American study on changes
in sales of supplements [40] reported a peak in sales of
St. John’s wort in 1998 followed by a decline until 2004
and then followed by stable sales until 2006. Further,
similar as our study, other studies in Europe and the
US observed a significant rise in the use of opioid anal-
gesics [41–43], and Z-drugs [44] and a decrease in the
use of benzodiazepines [44–46] among older people. In
the present analyses we observed an increased use of
overall anti-dementia drugs. This tendency was con-
firmed by a population-based Spanish study [47] and a
Swedish study among residents of geriatric care [48].
The significant increase in the use of phytoceutical
anti-dementia (Ginkgo biloba) in our study was also re-
ported by an American study (1994–1999) [49], while a
later conducted American study (1998–2002) [50]
found a decrease in the use of Ginkgo biloba. In line
with our study too, significant increases in the use of
anti-epileptics were described by a Danish [51] and a
Canadian [52] study as well as by a study comparing
health record data of Spain, Denmark, Netherlands, the
UK and Germany [53].
Rises in the use of synthetic antidepressants, anti-
dementia, opioid analgesics and anti-epileptics might
reflect a more efficient diagnosing, greater choice of
medicines available, improved medical care for the eld-
erly and improved adherence to guidelines. A German
adaptation of the guidelines on Potential Inadequate
Medication (PIM) for the elderly [54, 55] recommends
for example to prescribe specific SSRIs (and other med-
icines) instead of a number of classical antidepressants
of the ATC class N06AA, which could explain the
significant rise in SSRI use among the elderly. The rea-
sons for the decrease in the use of phytoceutical
antidepressants (St. John’s wort) and the shift towards
new synthetical antidepressants are unclear as studies,
e.g. a meta-analysis of Cui (2016) [56] came to the
result that for the treatment of mild and moderate de-
pression St. John’s wort is equally effective as SSRIs and
has fewer side-effects. The decrease in benzodiazepine
use and a shift towards using more Z-drugs might re-
flect a growing concern about the side effects of benzo-
diazepines and a greater adherence to guidelines
advising to prescribed Z-drugs instead of long-lasting
benzodiazepines to older adults [54, 55]. Further, the
guidelines recommend that older people use valerian (and
other substances) instead of medium- and short-lasting
benzodiazepines [54, 55]. However, a decrease in the use
of valerian was found in our study. The increased use of
opioid analgesics among older adults might be beneficial
for pain reduction and improvement of physical function,
but can also impair mental health functioning [57] and
lead to falls and fractures [58].
Changes in long-term-use of psychotropic drugs
As in our study, increases in long-term antidepressants
use were also found for example in Finland [24] and the
US [59]. Also comparable to our study, the long-term
use of benzodiazepines decreased in a Finnish study
[24]. A Dutch study [60] reported a decline in moderate
duration of benzodiazepine use. Moderate duration of
use was defined as ≥1 month – ≤1 year while long-term
use was defined as ≥3 months in our study. Similar to
other studies [43, 61, 62] we observed a significant rise
in the long-term use of opioid analgesics among the
elderly.
The increase in long-term use of synthetical antide-
pressants could be due to a better tolerability of new
substances and a rise of treatment in accordance with
medical guidelines. Increased use and long-term use of
opioid analgesics could be due to changes in drug polit-
ics and due to rising diagnosis of pain [61, 62]. It might
reflect a more adequate treatment of pain among older
Fig. 1 Prevalence of long-term psychotropic drug use among adults aged 60–79 years in Germany. National Health Interview and Examination
Surveys GNHIES98 (1997–99) and DEGS1 (2008–11)
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adults, although benefits and risks of long-term opioid
use are discussed controversial in literature [4, 6, 43, 57].
Changes in psychotropic drug use according to
socio-demographic and health-related factors
In our analyses people with a lower social status were
more likely to use opioids and those with a worse health
status more likely to use overall psychotropic drugs and
opioids, with gaps widening compared to their counter-
parts. A study comparing data from Canada, Albania,
Colombia and Brazil [63] found a higher psychotropic
drug use among people with a lower social status in
Canada but not in Latin America. In Albania a lower
social status was a predictor for higher use of anxiolytics,
sedatives and hypnotics while antidepressants use was
generally low [63]. In a Scottish study [41] use of strong
opioids (classified according to the British National For-
mulary 2012) increased significantly and was associated
with a lower social status and polypharmacy. In a Dutch
study [60] benzodiazepine use remained stable between
1992 and 2002 and was associated with female sex,
lower social status and a worse health status. Significant
increases of psychotropic drug use among people with a
worse health status were also reported by a Spanish
study [36], while a Brazilian study [64] observed a sig-
nificant rise in the use of antidepressants, which was
Fig. 2 a. Overall psychotropic drug use and risky drinking among adults aged 60–79 years in Germany by sex, social status and self-assessed
health status. National Health Interview and Examination Surveys GNHIES98 (1997-99) and DEGS1 (2008-11). Risky drinking: Average daily
consumption of alcohol ≥10 g for women, and ≥20 g for men. b: Use of antidepressants, benzodiazepines and opioid analgesics among
adults aged 60–79 years in Germany by sex, social status and self-assessed health status. National Health Interview and Examination Surveys
GNHIES98 (1997–99) and DEGS1 (2008–11). Antidepressants: Synthetics (N06A) and St. John’s wort (N06AP01). Benzodiazepines: N05BA, N05CD,
N03AE01 and N05CF. Opioid analgesics: N02A
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associated with increased income and reasonable self-
assed health status. Further, we found a decreasing
benzodiazepine use in men which was confirmed by a
Dutch study [60]. Our analyses showed a higher preva-
lence of psychotropic drug use in women and a growing
gender gap over time which was also reported by other
studies [24, 38, 43].
Differences in psychotropic drug use according to so-
cial status reflect the general social inequality of health
and a higher use of psychotropic drugs among people
with a worse health status was expectable. Reasons for
older women’s higher consumption of psychotropic
drugs might be rooted in different perceptions of mental
or physical health [65], different patterns concerning the
use of health-services [66], health professionals being
more likely to prescribe psychotropic drugs to women
[65], more inappropriate prescribing for women [66, 67]
or differences in symptom patterns leading to under-
diagnosing in men [68].
Strengths and limitations
One of the strengths of our study is the large sample size
of nation-wide and population based representative data.
This allows generalization to the community dwelling
population of Germany. Recall-bias concerning psycho-
tropic drug use was minimized by limiting the observa-
tion window to 7 days prior to interview and by asking
participants to bring along original packages of their
medicines. Furthermore, recording all consumed medi-
cines including privately prescribed, phytoceutical and
OTC products, allowed us to analyse the “real” drug use
among the community dwelling population. This is par-
ticularly relevant for the use of benzodiazepines as in
Germany about 50% of benzodiazepine prescriptions are
prescribed privately [7] and therefore are not recorded
by health insurance data.
Limitations of our study include a selection bias as
institutionalized people were excluded. Also, people
with severe illnesses or cognitive impairments are un-
derrepresented as they might not be able to come to
the study centers. Further, the age limit of 79 years ex-
cludes those who might be mostly affected by medica-
tion use. An underestimation of psychotropic drug use
among the elderly is therefore likely. It is also likely that
we underestimated risky drinking as older people with
severe alcohol problems might not come to examin-
ation sites.
Conclusion
Psychotropic drug use among the elderly remained
stable at a high level in Germany. Changes in the use of
some psychotropic drug subgroups as well as of alcohol
consumption patterns have been observed with signifi-
cant rises in the use of synthetical antidepressants,
opioid analgesics, Z-drugs, anti-dementia drugs, anti-
epileptics, daily and moderate alcohol consumption.
Female sex, lower social status and a worse health status
were associated with psychotropic drug use in both sur-
veys and gaps were growing compared to their counter-
parts. Rising alcohol consumption and rises in the use of
potentially addictive drugs among the elderly are devel-
opments which could point towards a growing public
health problem. Further studies are needed to evaluate
health outcomes following changes in psychotropic sub-
stance use among the elderly.
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